 ( Clin Pathol 1996;49:897-902) 
An aetiological role for EBV in many EBV associated malignancies may be mediated by LMP-1.'4 -By contrast, the pathogenic role of EBNA2 in vivo seems to be restricted, as expression of EBNA2 has been detected only in B cell lymphomas arising in immunocompromised patients.3 [18] [19] [20] Recently, several reports have indicated that EBNA1 is not only involved in viral plasmid DNA replication and maintenance of viral episomes in the cell,'2 but may also play a more active role in the pathogenesis of lymphomas.21 22 25 26 promoter.
It is possible that the putative oncogenic effect of EBNA1 is related to its level of expression. Recently, EBNA1 specific antibodies became available, enabling the detection of EBNA1 on conventional paraffin wax embedded tissue sections.27 Using these antibodies, we investigated whether there are differences in the level of expression of EBNA1 in benign and malignant lesions harbouring EBV. Reverse transcription polymerase chain reaction (RT-PCR) analysis was also carried out to investigate whether such differences could be explained by differential usage of the EBNA1 promoters. 
Methods

IMMUNOHISTOCHEMISTRY
The specificities of rat monoclonal antibodies 1H4-1 and 2B4-1 directed against EBNA1 have been described elsewhere.27 Immunohistochemistry was performed on paraffin wax sections, fixed either in buffered formaldehyde or sublimate formaldehyde. Briefly, tissue sections were deparaffinised in xylene and incubated with hydrogen peroxidase to block endogenous peroxidase. After antigen retrieval in 0.1 mol/l citrate buffer, pH 6.0, for 10 minutes in a pressure cooker, tissue sections were washed, pre-incubated with normal serum and incubated with a mixture of 1H4-1 (rat IgG2a) and 2B4-1 (rat IgGl) for one hour at a dilution of 1 in 200. Subsequently, sections were incubated with biotinylated goat anti-rat followed by incubation with an ABC horse radish peroxidase (HRP) complex (Dako, Glostrup, Denmark). Amplification of signal intensity was obtained by deposition of biotinylated tyramine (BT) on the bound ABC-HRP complex through the enzymatic reaction between tyramine and HRP. 35 This was followed by a second incubation period with ABC-HRP. Diaminobenzidine (DAB) was used as the chromogen. Inclusion of this amplification step enhanced the staining intensities and revealed greater numbers of EBNA1 positive cells compared with the routine ABC method lacking this step.
In T and B cell lymphomas the number of EBER1/2 and EBNA1 positive cells was estimated visually, as described by Weiss et al,36 with slight modifications.8 Using a x12.5 ocular and a x25 objective for screening the tissue slides, lymphomas were divided into diffuse (over 100 cells per medium power field (mpf)), clustered (between 25 and 100 cells per mpf), scattered (less than 25 cells per mpf) or single cell (less than one cell per mpf) positive cases. Negative controls included isotype matched rat monoclonal antibodies.
RT-PCR
RT-PCR analysis was performed using intron flanking primers. Two primer combinations were used to detect EBNA1 specific transcripts. One set was used to detect Y3/U/K spliced transcripts, probably generated by the C/W promoter, and the other to detect Q/U/K spliced transcripts generated by the F/Q promoter. Cases were excluded if the mRNA seemed to be of poor quality, as determined by RT-PCR using primers specific for U1A37 and for rightward reading EBV transcripts from the Bam HI A region (BARFO), which is present in all tissue harbouring EBV. 38 The primer sequences and oligo probes used for analysis of EBNA1 and BARFO were as reported previously.1516 The conditions used for RNA isolation, RT-PCR analysis and Southern blot hybridisation have been described elsewhere. 39 In all experiments positive and negative controls were included to test the specificity and sensitivity of the RT-PCR conditions. Expression of EBNA 1 in benign and malignant tissues harbouring EBV analysis revealed that in one case EBNA1 specific transcripts were initiated by the F/Q promoter and in the other by the C/W promoter. Again, the EBER1/2 staining pattern was diffuse in all cases. Table 2 summarises the results. EBNA1 positive cells were detected in eight of nine EBV associated T cell lymphomas. Again, EBNA1 nuclear staining was seen, but the staining intensity was weaker than that observed in EBNA1 positive cells in the B cell lymphomas. Of the EBV associated T cell lymphomas, three were of nasal origin, all classified as pleomorphic medium and large cell lymphoma and all three had a diffuse EBER1/2 staining pattern. In contrast to the B cell lymphomas, diffuse EBNA1 and EBER1/2 staining patterns were observed in one case only. Clustered EBNA1 positive cells were detected in another case. No EBNA1 positive cells were found in the remaining case.
Results
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EBNAl EXPRESSION IN T CELL LYMPHOMAS
Of the six nodal T cell lymphomas, four were classified as pleomorphic medium and large cell lymphoma, one case was classified as large cell anaplastic lymphoma (LCAL) and one case was unspecified. A diffuse EBER1/2 staining pattern was observed in two cases, including the LCAL, and a clustered pattern was seen in the remaining four. RT-PCR analysis revealed that in three of five T cell lymphomas tested, EBNA1 transcripts were generated by the F/Q promoter. In the LCAL, however, EBNA1 transcripts were generated by the C/W promoter.
EXPRESSION OF EBNA1 IN PATIENTS WITH HODGKIN'S DISEASE
The data are summarised in ID) . In the other seven cases EBNA1 positive signals were relatively weak and were only detected in a minority of the H-RS cells. In some cases harbouring EBER1/2 positive small and medium sized cells, these cells were also EBNA1 positive. In one of the four EBNA1 positive cases tested, EBNA1 specific transcripts were generated by the F/Q promoter. In another case, transcripts were generated by both promotors. In two EBER1/2 positive, immunohistochemically EBNA1 negative cases, EBNA1 transcripts were derived from the F/Q promoter.
EXPRESSION OF EBNA1 IN BENIGN TISSUES HARBOURING EBV
In infectious mononucleosis the EBNA1 and EBER 1/2 staining patterns were very similar. EBNA1 positive lymphocytes were observed in both specimens of reactive lymphoid tissue harbouring scattered EBER1/2 positive lymphocytes ( fig 1E) . In the hyperplastic tonsil, EBNA1 transcripts were generated by the F/Q promoter (table 3) .
Discussion
Expression of EBNA1 was observed in all EBV associated B cell lymphomas, in eight of nine EBV associated T cell lymphomas, in all cases of infectious mononucleosis, and in some of the EBV associated cases of Hodgkin's disease. Moreover, in line with previous findings in peripheral blood lymphocytes of healthy EBV seropositive subjects,404' EBNA1 was expressed at the protein level in latently infected lymphocytes in reactive lymphoid tissues. EBNA1 was most strongly expressed in the EBV associated B cell lymphomas. In most cases a diffuse staining pattern was found, which was comparable with the EBER1/2 staining pattern. Contrasting results were found in EBV associated T cell lymphomas and particularly EBV associated cases of Hodgkin's disease. One T cell lymphoma did not express EBNA1 and in another six the number of EBNA1 positive cells was considerably smaller than the number of EBER1/2 positive cells. In agreement with previous findings,27 EBNA1 expression could only be detected in some EBV associated cases of Hodgkin's disease and generally only in a minority of H-RS cells. LMP-1, however, is usually expressed strongly in almost all H-RS cells in all EBV positive cases.42 Our findings, in contrast with those of Khan and Naase,43 suggest that EBNA1 is expressed in at least some cases of EBV associated Hodgkin's disease. 11 and 12, respectively) . Lower panel. Relatively faint QIUIK spliced (probably derivedfrom the Q promoter) EBNA1 specific signals were found in one clustered and t diffuse EBERI 12 positive T cell lymphomas (lanes 1-3) . Clear signals were found in on cell lymphoma arising in a patient without overt immune deficiency (lane 4), in four of post-transplant lymphomas (lanes 6-9) and in both EBVpositive cell lines. In these cas the QIUIK spliced EBNAI specific signals were probably generated by the F promoter.2' EBNA 1 specific transcripts were never detected in the EBV negative BJAB cell line (la 13.) As EBNA1 is essential for the maintena of viral episomes in the cell,'2 the restric expression of EBNA1 is some cases is proba because EBNA1 was present in concentrati below the detection limit of the antibo4 used. This hypothesis is 29 These data suggest that Q promoter usage results in lower levels of EBNA1 expression than C/W or F promoter usage. Although a (semi-)quantitative RT-PCR assay was not performed, this hypothesis was supported by the differences in signal intensity. Strong amplification signals were observed for both C/W and F promoter derived EBNA1 transcripts in the B cell lymphomas, whereas faint bands were found for the Q promoter derived EBNA1 transcripts in the diffuse EBER1/2 positive T cell lymphomas (fig 2) .
These different levels of EBNA1 expression may have implications for the pathogenic role of EBV in the different types of EBV associated lymphomas. It has been shown previously that activation of cellular oncogenes, such as c-myc, is associated with progression of posti5)n transplant lymphomas and AIDS related lym- 
